2026InterventionValve disease

GLUCO-TAVI

Therapy group: TAVI · Therapy: Glucocorticoids to prevent pacemaker after TAVI

Randomised pilot: periprocedural glucocorticoids were feasible and safe, with numerically fewer pacemakers at one month, but the difference was not statistically significant.

Published in EuroIntervention (2026)

Question: Can perioperative glucocorticoids reduce the need for permanent pacemaker implantation, the most common complication of TAVI?
Design: Pilot randomised 1:1 trial with an open-label, blinded-endpoint (PROBE) design in patients undergoing TAVI; electrocardiograms and inflammatory biomarkers were assessed before and after the intervention, at 1 month and at 1 year.
Population: Patients undergoing transcatheter aortic valve implantation (TAVI).
Intervention: Methylprednisolone 7 mg/kg one hour before the procedure, followed by prednisone 15 mg every 12 hours for 5 days.
Control: Standard care.
Primary outcome: Incidence of permanent pacemaker implantation at 1 month (primary efficacy endpoint).
Results: The primary outcome occurred in 16% of the control group and 8% of the intervention group (RR 0.50, 95% CI 0.16-1.55; p=0.23), a non-significant difference. There were also no significant differences in 1-year pacemaker implantation (RR 0.67, 95% CI 0.26-1.73; p=0.41) or new left bundle branch block (RR 1.12, 95% CI 0.66-1.89; p=0.66).
Safety: The intervention was safe, with no differences in complications, mortality (4% vs 12%; p=0.27) or adverse events.
Conclusion: Glucocorticoids in TAVI are feasible and safe, but the numerical difference in pacemaker implantation did not reach statistical significance.
Why it matters: As a pilot study, it provides a first signal of feasibility and safety for this anti-inflammatory strategy and supports larger trials to confirm its usefulness.

Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.

Some figures could not be verified automatically and were left out of this card.

Generated on October 14, 2026

Sources

Original publication on PubMed (PMID 42137921) ↗Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial.
Journal article (DOI) ↗

Videos explaining it

Glucocorticoids to reduce PPI after TAVI: the GLUCO-TAVI randomised trial: Original Research

EuroIntervention · EuroIntervention Journal ↗15:18Video page

Source: EuroIntervention Journal · YouTube
Date: 15 May 2026
Audio: English
Subtitles: MultilingualYouTube
Audio transl.: Unconfirmed · check ⚙YouTube

If you don't see subtitles in your language, turn on auto-translate from the player's settings gear (⚙).

No subtitles in your language?

First try the player's auto-translate: settings gear (⚙) → Subtitles/CC → Auto-translate. If the video has no subtitles at all, your phone or browser can write out what is said in real time. It runs on your own device: CanduCardio receives and stores nothing.

Android phone: Settings → Accessibility → Live Caption (on many models a captions button also appears when you press the volume key). Some models, such as Pixel or recent Samsung Galaxy phones, can also translate them.
Chrome (computer or Android): Settings → Accessibility → Live Caption. For some languages it can also translate them.
Windows 11: Settings → Accessibility → Captions (or press Windows + Ctrl + L).
iPhone, iPad or Mac: Settings → Accessibility → Live Captions (depending on language and model).
TVs: almost none have this feature; use the player's auto-translate (⚙).

Podcasts explaining it

Glucocorticoids to reduce PPI after TAVI: the GLUCO-TAVI randomised trial: Original Research
EuroIntervention · EuroIntervention | Editor's Choice ↗15 minEpisode page
Source
EuroIntervention · Apple Podcasts
Date
15 May 2026
Audio
English
Translation
TextGoogle Chrome
Audio transl.
None

Educational content only. CanduCardio is intended for healthcare professionals and CanduTV for the general public. It does not replace clinical judgment or professional consultation.